hepatitis b immune globulin

REMS

Prevents hepatitis B infection in patients who are known to have been exposed, including neonates born to HBsAg-positive women, by providing passive immunity.

Contraindicated in:

Use Cautiously in:

Derm: pruritus, rashes, urticaria

Local: erythema at IM site, pain, swelling, tenderness

MS: joint pain

Neuro: dizziness, faintness, malaise, weakness

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Drug-drug:

IM (Adults ): 0.06 mL/kg (usual dose 3–5 mL) within 7 days of exposure, repeated 28–30 days after exposure.
IM (Neonates ): 0.5 mL within 12 hr of birth.

~~BayHep B,~~ Nabi-HB

An immune gamma-globulin fraction containing high titers of antibodies to the hepatitis B surface antigen. Confers passive immunity to hepatitis B infection.

Therapeutic effects:

Therapeutic Classification: vaccines/immunizing agents

Pharmacologic Classification: immune globulins

Absorption: Slowly absorbed after IM administration.

Distribution: Unknown. Probably crosses the placenta.

Metabolism/Excretion: Unknown.

Half-Life: 21 days.

(development of anti-HBs antibodies)

ROUTE	ONSET	PEAK	DURATION
IM	1–6 days	3–11 days	2–6 mo

Explain to patient the use and purpose of hepatitis B immune globulin therapy. Discuss methods of transmission and vaccination for prophylaxis.
Advise patient to report symptoms of anaphylaxis immediately.
Inform patient that pain, tenderness, swelling, and erythema at the injection site may occur after IM injections.

hep-a-TITE-iss B i-MYOON GLO-byoo-lin